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Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes ﬁbrosis and vasculopathy in skin,
lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose
naltrexone hydrochloride (LDN) for pruritus, pain, and quality of life (QOL) in other GIT diseases have been successful. In this
case series we report three patients that had signiﬁcant improvement in pruritus and total GIT symptoms as measured by the
10-point faces scale and the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0
(UCLA SCTC GIT 2.0) questionnaire. This small case series suggests LDN may be an eﬀective, highly tolerable, and inexpensive
treatment for pruritus and GIT symptoms in SSc.
1.Introduction
Systemic sclerosis (SSc; scleroderma) is an autoimmune
disease characterized by vasculopathy and ﬁbrosis of mul-
tiple organs including the skin, lungs, and gastrointestinal
tract (GIT). This chronic disease process results in pain
and pruritus, two distinct, but interacting phenomena [1].
Pruritus is most common in the early stages of disease and
may subside as the disease progresses [2]. SSc patients that
complainofpruritushavemoresigniﬁcantskininvolvement,
more severe ﬁnger ulcers, worse respiratory symptoms, and a
greater number of GIT complaints [3]. Of interest, pruritus
is independently associated with GIT symptoms in SSc [3].
Although pruritus is associated with signiﬁcant disability,
management guidelines for pruritus in SSc do not exist [4].
Pruritus is also a feature of primary biliary cirrhosis
(PBC),whichoccursmorecommonlyinSScthanthenormal
population [5]. There is a known association with PBC
and oxidative stress as well as endothelial dysfunction [6].
Pharmaceutical management suggestions for treatment of
pruritusinPBCincludecholestyramine,rifampin,sertraline,
and naloxone [7]. More recently, pilot trials of low-dose
naltrexone hydrochloride (LDN), which is a pharmaceutical
similar to naloxone, have recently gained increasing recogni-
tion for treating chronic pain associated with ﬁbromyalgia,
multiple sclerosis, and Crohn’s disease [8–10].
Evidence supporting the hypotheses that increased
opioid-mediated neurotransmission in the brain is a mech-
anism of pruritus and that central opioidergic tone is
increased in cholestasis provides a rationale for treating the
pruritus of cholestasis with opiate antagonists in PBC [11].
Another potential mechanism of action of LDN is through
attenuation of the production of proinﬂammatory cytokines
and superoxides potentially mediated by activity of toll-like
receptor 4 [12]. Modulation of mitochondrial apoptosis has
also been proposed as a mechanism of LDN [13]. In SSc,2 International Journal of Rheumatology
oxidative stress may be important in disease pathogenesis
[13]. Thus, an agent that potentially modulates oxidative
stress is attractive as an emerging therapeutic in SSc. Given
the putative mechanisms of action of LDN and the roles of
these various pathways in SSc, our hypothesis is that LDN
may be a reasonable agent to treat pruritus in SSc.
2. Patientsand Methods
In this case series we report three SSc patients who presented
to the University of UtahSSc Center with the chief complaint
of pruritus. All were white females between the ages of 34
and 56. Two patients were of diﬀuse cutaneous SSc subtype
(dSSc); the other one was limited SSc subtype (lSSc) [14].
One of the dSSc patients and the lSSc had tendon friction
rubs. None had scleredema. The disease duration from the
ﬁrst non-Raynaud’s phenomenon symptom varied from 1
year to 11 years. Raynaud’s phenomenon onset was within
the same year of diagnosis in two patients, and three years
prior in one patient. All patients reported pruritus as an
important feature of disease since onset of SSc and did
not attribute it directly to change in skin thickening or
GI manifestations. They all reported that “itchiness” of the
skin had been present for >6 weeks and was unresponsive
to antihistamines on all days. None had urticaria. They all
denied a history of eczema or skin conditions other than SSc,
any new product, or infectious exposures and attributed this
symptom to SSc. A ten-point faces scale was used to assess
pruritus. On this scale 0, is no symptoms, 1 very mild, 2
discomforting, 3 tolerable, 4 distressing, 5 very distressing,
6 intense, 7 very intense, 8 utterly horrible, 9 excruciating,
10 unimaginable/unspeakable [15]. It has been used in other
clinical trials of pruritus [16]. Each of our participants
ranked their pruritus >5.
All patients completed a University of Los Angeles
Scleroderma Clinical Trials Consortium Gastrointestinal
Tract Questionnaire (GIT 2.0). The GIT 2.0 is patient-
reported outcome measure to assess health-related quality of
life (HRQOL) and GIT severity in SSc [17, 18]. This 34-item
instrument has seven scales: reﬂux, distention/bloating,
diarrhea, fecal soilage, constipation, emotional well-being,
and social functioning and a total GI score (a higher score
denoted worse HRQOL). All scales are scored from 0.0
(better HRQOL) to 3.0 (worse HRQOL) except diarrhea
and constipation scales that range from 0.0 to 2.0 and 0.0
to 2.5, respectively. The total GI score is the average of 6
of 7 scales (excludes constipation), and total GI score is
scored from 0.0 (better HRQOL) to 3.0 (worse HRQOL).
Each scale is further divided into 3 groups by severity:
none-to-mild, moderate, and severe-to-very severe. These
were calculated based on anchors included in the original
published data and data collected in a recent National
Scleroderma Foundation online survey and available online
at http://uclascleroderma.researchcore.org. The instrument
takes 6–8 minutes to be completed and has been shown to
have acceptable reliability and validity [17, 19]. Additionally
each patient had a modiﬁed Rodnan skin score (mRSS) as
part of their routine care at baseline (Table 1).
Baseline laboratories were obtained in all patients as per
routine care. All were antinuclear antibody (ANA) positive.
A marker of inﬂammation (C-reactive protein) was normal
in all patients. None of the patients had an eosinophilia
(<0.4k/μL) on peripheral blood smear. Anti-tissue transglu-
taminase and antimitochondrial antibody were negative in
all patients. Two patients had skin biopsy performed as part
of another clinical study. A computer-assisted image analysis
of two of the biopsy specimens revealed that at baseline there
was not an increase in mast cells greater than those present
in a healthy control (Figures 1 and 2).
From a treatment perspective, all patients were RNA
polymerase III positive, making a trial of corticosteroids
for treatment of pruritus an unattractive option due to an
increase risk of scleroderma renal crisis [20]. They all denied
depression and were resistant to a trial of sertraline. None
consumed alcohol or were taking narcotics for pain. One
patient was on methotrexate for arthritis. The other two
patients were not on immunosuppression medications. All
patients denied respiratory complaints, had no evidence of
pulmonary arterial hypertension on echocardiogram, and
had normal pulmonary function tests. No patients had digi-
talulcersormetclinicalcriteriaforﬁbromyalgia.Allhadnor-
mal colonoscopies without evidence of collagenous colitis.
Each patient was initiated on LDN 2mg by mouth at
bedtime for the ﬁrst month. Using dosing recommendations
from another trial and phone call monitoring for adverse
eﬀects, the dose was increased by 1mg by mouth at bedtime
each week (0.5mg the ﬁnal week) up to a maximum dose
of 4.5mg [9]. One patient requested to maintain the dose of
2mg bymouthatbedtime, asshefeltit wasworkingwelland
did not wish to incur additional cost. The other two patients
reached the 4.5mg dose. All patients were seen in clinic for
followupaftertwomonthsoftreatment.Allpatientsrepeated
the GIT 2.0, and a mRSS was done at each visit. No other
medicationchange,includinguseofover-the-counteragents,
was allowed for any of these patients during the treatment
period. However, nonmedicinal changes were allowed. One
patient implemented head-of-the-bed elevation for reﬂux
management, and two patients increased ﬂuid and dietary
ﬁber intake for symptoms of constipation.
3. Results
All patients reported an improvement in pruritus on a
Faces Scale after initiating LDN (Table 1)[ 15]. In two
diﬀerent patients, pruritus completely resolved on LDN. In
twopatientsatrendinimprovementinmRSSwasseenattwo
months, which is not clinically signiﬁcant [21]. However, all
patients reported feeling that skin was objectively softer. In
all patients there was an improvement in total GIT 2.0 scores
as well as in constipation and distention/bloating subscales.
Repeat skin biopsy specimens were not obtained. No adverse
drug eﬀects were reported with the exception of two nights
of insomnia reported in a single patient.
4. Discussion
Pruritus is a common symptom in SSc, with limited treat-
ment options. The pathogenesis of chronic (>6w e e k sInternational Journal of Rheumatology 3
Table 1: Clinical features of systemic sclerosis participants.
Patient Disease onset∗,
subtype
Pre-LDN
pruritus
Post-LDN
pruritus
Pre-LDN
mRSS
Post-LDN
mRSS
Pre-LDN UCLA SCTC GIT
2.0
Post-LDN UCLA SCTC
GIT 2.0
1 2 years, diﬀu s e 1 042 8 2 4
Total: 0.355
(i) Reﬂux: 0.63
(ii) Distention: 0.5
(iii) Soilage: 0
(iv) Diarrhea: 0
(v) Constipation: 1.25
(vi) Social: 0
(vii) Emotional: 0.11
Total: 0.302
(i) Reﬂux: 0.5
(ii) Distention: 0.5
(iii) Soilage: 0
(iv) Diarrhea: 0
(v) Constipation: 1
(vi) Social: 0
(vii) Emotional: 0.11
2 11 years, diﬀuse 6 0 19 17
Total: 0.395
(i) Reﬂux: 0.63
(ii) Distention: 1.75
(iii) Soilage: 0
(iv) Diarrhea: 0.5
(v) Constipation: 0.5
(vi) Social: 0.17
(vii) Emotional 0.22
Total: 0.216
(i) Reﬂux: 0.38
(ii) Distention: 0.5
(iii) Soilage: 0
(iv) Diarrhea: 0
(v) Constipation: 0.25
(vi) Social: 0.17
(vii) Emotional 0.22
3 1 year, limited 8 0 12 12
Total: 0.54
(i) Reﬂux: 0.25
(ii) Distention: 1.5
(iii) Soilage: 0
(iv) Diarrhea: 0
(v) Constipation: 1.25
(vi) Social: 0.33
(vii) Emotional 0.44
Total: 0.216
(i) Reﬂux: 0.13
(ii) Distention: 0.5
(iii) Soilage: 0
(iv) Diarrhea: 0
(v) Constipation: 0.5
(vi) Social: 0.17
(vii) Emotional 0.22
∗First non-Raynaud’s phenomenon symptom; LDN: low-dose naltrexone; mRSS: modiﬁed Rodnan skin score; UCLA SCTC GIT 2.0: University of California
Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0.
(a) (b)
Figure 1:Biopsyspecimensfrompatient1:H&E-stainedsectionshowsmoderateperivascularandperiadnexalinﬂammationandthickening
of dermal collagen (20X). There are several mast cells in perivascular, interstitial, and periadnexal distribution with granular-appearing
cytoplasm (IHC mast cell tryptase 20X).
duration) pruritus is complex and involves a network of
resident cells (such as mast cells, keratinocytes, and sensory
neurons) and transient inﬂammatory cells within the skin
[22]. Pruritus in SSc is independently associated with GI
symptoms [3]. Because of the association of pruritus with
quality of life (QOL) in SSc, more attention to potential
methods for intervention is warranted [23]. his small case
series suggests a potential role for LDN for SSc with pruritus.
Additionally, a possible improvement in mRSS and in GIT
symptoms may also result from use of LDN.
Autoimmune gastrointestinal disorders such as inﬂam-
matory bowel disease (IBD), gluten-sensitive enteropathy,
and PBC have also been associated with pruritus [24].
Evidence supports that increased opioid-mediated neuro-
transmission in the brain may be a mechanism of pruritus
in PBC [11]. LDN has been found to improve QOL in IBD4 International Journal of Rheumatology
(a) (b)
Figure 2: Biopsy specimens from patient 3: H&E-stained section shows scant perivascular inﬂammation and thickening of dermal collagen
(20X). There are scattered mast cells in perivascular and interstitial distribution with granular-appearing cytoplasm (IHC mast cell tryptase
20X).
[10]. Although the real biological mechanism of LDN is
not known, LDN may modulate pruritus through opioid-
mediated actions or a reduction of inﬂammatory mediators
[25, 26]. As such, a better understanding of the interaction of
the GIT and pruritus is warranted.
SSc patients commonly have diarrhea, constipation, and
distention/bloating that may mimic GIT hypersensitivity
[27]. Whether the GIT is responsible for the pruritus in
SSc or whether the GIT and skin are reacting to a similar
stimulusorendogenousimmuneresponseisunknown.Mast
cells have been suggested to have an important role in SSc
as well as in functional bowel disorders [28, 29]. However,
computer-assistedanalysisofskinbiopsyspecimensintwoof
our patients did not reveal an abnormal percentage of mast
cells.
Clearly a larger number of patients and a double-
blind placebo-controlled trial are needed to deﬁne the
therapeutic potential of LDN in SSc. The patients’ subjective
observation of “softer skin” was not validated by a signiﬁcant
change in mRSS and could be attributed to the natural
history of disease rather than to naltrexone. Additionally,
intraobserver variability could explain the improvement in
mRSS. Psychological and physiological predictors of pruritus
response as well as minimally important diﬀerences in the
ten-point faces scale need to be deﬁned. Gastrointestinal
biopsy specimens would have been helpful for correlating
to skin biopsy specimens for deﬁning potential morphologic
and histochemical change. Nonetheless, this series suggests
LDN may be an eﬀective, highly tolerable, and inexpensive
treatmentforpruritusinSScandfurthersupportsapotential
role for computer-assisted quantiﬁcation of inﬂammatory
cell types in skin biopsies to guide selection of therapeutics.
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